Arcutis Biotherapeutics had its Relative Strength (RS) Rating upgraded from 80 to 84 Tuesday.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique rating identifies share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the best stocks often have an RS Rating of at least 80 as they begin their biggest climbs.
Arcutis Biotherapeutics is building a consolidation with a 17.75 buy point. See if the stock can clear the breakout price in heavy volume.
The company reported 0% earnings growth last quarter, while sales growth came in at 33%.
The company holds the No. 52 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
